2021
PET-Based Quantification of Baseline Metabolic Tumor Burden Improves Risk Stratification in High-Risk Hodgkin Lymphoma: A Children's Oncology Group Study
Milgrom S, Kim J, Hoppe B, Pei Q, Wu Y, Lo A, Kessel S, McCarten K, Roberts K, Hodgson D, Schwartz C, Friedman D, Kelly K, Cho S. PET-Based Quantification of Baseline Metabolic Tumor Burden Improves Risk Stratification in High-Risk Hodgkin Lymphoma: A Children's Oncology Group Study. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s79-s80. DOI: 10.1016/j.ijrobp.2021.07.192.Peer-Reviewed Original ResearchRapid early respondersSlow early respondersMetabolic tumor volumeTotal lesion glycolysisBaseline metabolic tumor burdenHigh-risk Hodgkin lymphomaBaseline tumor burdenMetabolic tumor burdenTumor burdenIntensive therapyHodgkin's lymphomaPET scansEarly respondersCutoff valueEvent-free survival rateChildren's Oncology Group studyPositron emission tomography scanMaximum standardized uptake valueCycles of chemotherapyInitial disease burdenNodular sclerosis histologyResponse-adapted approachBaseline PET scanKaplan-Meier analysisAge 15.5 years
2000
Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy
Elconin J, Roberts K, Rizzieri D, Vermont C, Clough R, Kim C, Dodge R, Prosnitz L. Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy. International Journal Of Radiation Oncology • Biology • Physics 2000, 48: 1097-1105. PMID: 11072168, DOI: 10.1016/s0360-3016(00)00695-7.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleHodgkin DiseaseHumansMaleMechlorethamineMediastinal NeoplasmsMiddle AgedNeoplasm StagingPrednisoneProcarbazineRadiotherapy DosageRetrospective StudiesTreatment FailureVinblastineVincristineConceptsLarge mediastinal adenopathyHodgkin's disease patientsComplete responseDisease patientsInduction chemotherapyInduction failureGallium scanMediastinal adenopathyModality therapyRT doseComplete clinical stagingLow-dose radiotherapyResidual radiographic abnormalitiesCycles of chemotherapyFailure-free survivalPhase III trialsPatterns of failureConsolidation radiationChemotherapy regimensCR patientsIII trialsOverall survivalClinical stagingHD patientsRadiographic abnormalities